Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 367.83 Million USD | 16.33% |
| 2022 | 316.19 Million USD | 8.94% |
| 2021 | 290.25 Million USD | 13.03% |
| 2020 | 256.79 Million USD | 3.26% |
| 2019 | 248.68 Million USD | 46.97% |
| 2018 | 169.2 Million USD | 20.44% |
| 2017 | 140.48 Million USD | 49.49% |
| 2016 | 93.97 Million USD | 36.19% |
| 2015 | 69 Million USD | 45.77% |
| 2014 | 47.34 Million USD | 45.17% |
| 2013 | 32.6 Million USD | 44.51% |
| 2012 | 22.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 92.7 Million USD | -9.2% |
| 2024 Q2 | 100.61 Million USD | 8.54% |
| 2024 Q3 | 98.74 Million USD | -1.86% |
| 2023 Q3 | 87.54 Million USD | -2.04% |
| 2023 Q2 | 89.37 Million USD | 0.62% |
| 2023 FY | 367.83 Million USD | 16.33% |
| 2023 Q4 | 102.09 Million USD | 16.62% |
| 2023 Q1 | 88.82 Million USD | 1.23% |
| 2022 Q3 | 76.01 Million USD | -17.02% |
| 2022 Q4 | 87.73 Million USD | 15.42% |
| 2022 FY | 316.19 Million USD | 8.94% |
| 2022 Q1 | 70.82 Million USD | -4.6% |
| 2022 Q2 | 91.61 Million USD | 29.35% |
| 2021 Q2 | 74.55 Million USD | 18.08% |
| 2021 Q4 | 74.24 Million USD | -5.2% |
| 2021 Q3 | 78.31 Million USD | 5.04% |
| 2021 FY | 290.25 Million USD | 13.03% |
| 2021 Q1 | 63.14 Million USD | -2.92% |
| 2020 Q1 | 75.41 Million USD | -5.3% |
| 2020 Q2 | 57.08 Million USD | -24.31% |
| 2020 Q3 | 59.25 Million USD | 3.79% |
| 2020 Q4 | 65.03 Million USD | 9.76% |
| 2020 FY | 256.79 Million USD | 3.26% |
| 2019 Q4 | 79.64 Million USD | 25.97% |
| 2019 FY | 248.68 Million USD | 46.97% |
| 2019 Q3 | 63.22 Million USD | 10.97% |
| 2019 Q2 | 56.97 Million USD | 16.61% |
| 2019 Q1 | 48.85 Million USD | 8.42% |
| 2018 Q4 | 45.06 Million USD | 0.51% |
| 2018 FY | 169.2 Million USD | 20.44% |
| 2018 Q2 | 41.24 Million USD | 8.38% |
| 2018 Q1 | 38.06 Million USD | 4.31% |
| 2018 Q3 | 44.83 Million USD | 8.69% |
| 2017 Q4 | 36.48 Million USD | 7.49% |
| 2017 FY | 140.48 Million USD | 49.49% |
| 2017 Q1 | 30.42 Million USD | 9.07% |
| 2017 Q2 | 39.62 Million USD | 30.26% |
| 2017 Q3 | 33.94 Million USD | -14.34% |
| 2016 FY | 93.97 Million USD | 36.19% |
| 2016 Q2 | 22.07 Million USD | 14.08% |
| 2016 Q3 | 24.66 Million USD | 11.71% |
| 2016 Q1 | 19.35 Million USD | 3.55% |
| 2016 Q4 | 27.89 Million USD | 13.11% |
| 2015 FY | 69 Million USD | 45.77% |
| 2015 Q4 | 18.68 Million USD | 7.33% |
| 2015 Q3 | 17.41 Million USD | -12.31% |
| 2015 Q2 | 19.85 Million USD | 52.08% |
| 2015 Q1 | 13.05 Million USD | -8.33% |
| 2014 Q2 | 11 Million USD | 6.51% |
| 2014 Q3 | 11.76 Million USD | 6.89% |
| 2014 Q1 | 10.33 Million USD | 16.11% |
| 2014 Q4 | 14.24 Million USD | 21.09% |
| 2014 FY | 47.34 Million USD | 45.17% |
| 2013 Q3 | 8.89 Million USD | 15.21% |
| 2013 Q1 | 6.82 Million USD | 0.0% |
| 2013 Q2 | 7.72 Million USD | 13.24% |
| 2013 Q4 | 8.89 Million USD | 0.0% |
| 2013 FY | 32.6 Million USD | 44.51% |
| 2012 FY | 22.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 97.659% |
| Allurion Technologies Inc. | 120.57 Million USD | -205.068% |
| Artivion, Inc. | 223.43 Million USD | -64.628% |
| Avanos Medical, Inc. | 375.5 Million USD | 2.041% |
| Butterfly Network, Inc. | 162.46 Million USD | -126.408% |
| Butterfly Network, Inc. | 162.46 Million USD | -126.408% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 64.886% |
| Boston Scientific Corporation | 7.47 Billion USD | 95.081% |
| Perspective Therapeutics, Inc. | 17.42 Million USD | -2010.846% |
| CONMED Corporation | 564.24 Million USD | 34.809% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 88.099% |
| Paragon 28, Inc. | 210.1 Million USD | -75.077% |
| Globus Medical, Inc. | 887.16 Million USD | 58.538% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | 35.296% |
| Integer Holdings Corporation | 250.95 Million USD | -46.572% |
| Medtronic plc | 16.12 Billion USD | 97.719% |
| Nevro Corp. | 389.36 Million USD | 5.53% |
| Owlet, Inc. | 51.21 Million USD | -618.163% |
| Penumbra, Inc. | 590.87 Million USD | 37.747% |
| Vicarious Surgical Inc. | 80.66 Million USD | -355.999% |
| Smith & Nephew plc | 3.46 Billion USD | 89.39% |
| Sonendo, Inc. | 68.46 Million USD | -437.261% |
| STERIS plc | 1.4 Billion USD | 73.733% |
| Stryker Corporation | 9.2 Billion USD | 96.006% |
| Vapotherm, Inc. | 66.02 Million USD | -457.116% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 88.772% |